01345.HK
Shanghai Pioneer Holding Ltd
HKSE · Healthcare · Medical - Pharmaceuticals · CN
HKD 2.16
−3.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.6B | 1.3B | 1.5B | 1.6B | 1.6B |
| Cost of Revenue | 1.3B | 656.3M | 847.8M | 898.4M | 775.6M |
| Gross Profit | 1.3B | 627.1M | 683.2M | 668.2M | 780.5M |
| Operating Expenses | |||||
| R&D Expense | 9.3M | — | — | — | — |
| SG&A Expense | 978.2M | 486.7M | 496.8M | 534.7M | 548.3M |
| General & Admin Expense | 269.0M | 137.6M | 133.8M | 112.1M | 82.1M |
| Selling & Marketing Expense | 713.6M | 349.4M | 363.2M | 422.6M | 467.7M |
| Other Expenses | — | — | — | (14.0K) | — |
| Total Operating Expenses | 987.5M | 486.7M | 496.8M | 534.7M | 548.3M |
| Cost and Expenses | 2.3B | 1.1B | 1.3B | 1.4B | 1.3B |
| Operating Income (EBIT) | 289.8M | 140.4M | 186.4M | 133.5M | 232.2M |
| Non-Operating | |||||
| Interest Income | 9.1M | 5.4M | 3.8M | 585.0K | 2.9M |
| Interest Expense | 2.7M | 2.4M | 2.4M | 2.5M | 1.7M |
| Net Interest Income | 6.3M | 3.0M | 1.4M | (1.9M) | 1.2M |
| Other Non-Op Income/Expense | 36.9M | 7.9M | 26.7M | 36.8M | 62.3M |
| Non-Operating Income (excl Interest) | (9.7M) | — | 7.6M | (2.7M) | — |
| EBT (Pre-Tax Income) | 326.7M | 148.3M | 213.1M | 170.3M | 294.5M |
| Income Tax Expense | 108.8M | 43.2M | 67.7M | 51.5M | 64.5M |
| Bottom Line | |||||
| Net Income | 227.4M | 114.4M | 151.6M | 145.7M | 235.3M |
| Earnings from Cont. Ops | 217.9M | 105.1M | 145.4M | 121.8M | 229.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 227.4M | 114.4M | 151.6M | 145.7M | 235.3M |
| Per Share | |||||
| Basic EPS | HK$0.20 | HK$0.10 | HK$0.13 | HK$0.12 | HK$0.20 |
| Diluted EPS | HK$0.20 | HK$0.10 | HK$0.13 | HK$0.12 | HK$0.20 |
| Revenue Per Share | HK$2.24 | HK$1.11 | HK$1.32 | HK$1.33 | HK$1.31 |
| Shares | |||||
| Basic Shares Outstanding | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B |
| Diluted Shares Outstanding | 1.2B | 1.2B | 1.2B | 1.2B | 1.2B |
| Profitability Metrics | |||||
| EBITDA | 362.5M | 172.4M | 215.3M | 201.9M | 245.4M |
| D&A | 63.1M | 31.9M | 28.9M | 18.9M | 13.2M |
| EBIT | 299.4M | 140.4M | 186.4M | 182.9M | 232.2M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026